Skip to main content
. 2022 Mar 30;13(4):8382–8395. doi: 10.1080/21655979.2022.2036891

Figure 3.

Figure 3.

E2F2 is the target gene of miR-631, and elevated E2F2 facilitates the malignant behavior of NSCLC.

A. Test of E2F2 expression in NSCLC and normal tissues was via RT-qPCR, Western blot and IHC; B. Examination of E2F2 in NSCLC cell lines and human normal bronchial epithelial cell lines was via RT-qPCR and Western blot; C. Test of E2F2 in A549 cells after elevation of miR-631 was via Western blot; D. Binding sites at Bioinformatics website; Prediction of miR-631 and E2F2 was via https://cm.jefferson.edu/rna22/ andE. Analysis of the targeting of miR-631 with E2F2 was with the luciferase experiment; F: Examination of E2F2 in A549 cells after augmentation of E2F2 was via Western blot; G. Test of A549 cell proliferation after elevation of E2F2 was via plate clone; H. Examination of A549 cell apoptosis after augmentation of E2F2 was via flow cytometry; I. Test of A549 cell invasion and migration after elevation of E2F2 was via Transwell; J. Examination of the phosphorylation of PI3K/Akt in A549 cells after elevation of E2F2 was via Western blot. The value was presented as mean ± SD (n = 3). * P < 0.05.